LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

89.82 -1.9

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

86.33

Максимум

92.81

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+45.24% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-565M 5.9B
Предишно отваряне	91.72
Предишно затваряне	89.82

Настроения в новините

By Acuity

72%

28%

320 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.05.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on AI Enthusiasm -- Market Talk

11.05.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Rises on Possible Position Adjustments -- Market Talk

11.05.2026 г., 22:37 ч. UTC

Пазарно говорене

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11.05.2026 г., 22:32 ч. UTC

Печалби

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11.05.2026 г., 22:02 ч. UTC

Пазарно говорене

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11.05.2026 г., 21:49 ч. UTC

Печалби

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11.05.2026 г., 21:42 ч. UTC

Пазарно говорене

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11.05.2026 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

CSG Systems Sale to NEC Gets CFIUS Clearance

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv 1Q Loss/Shr $2.35 >OVV

11.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

11.05.2026 г., 20:44 ч. UTC

Печалби

Steris: Board Approves New $1B Shr Repurchase Program >STE

11.05.2026 г., 20:43 ч. UTC

Печалби

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Rev $136.4M >CLSK

11.05.2026 г., 20:30 ч. UTC

Печалби

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Cont Ops EPS $2.24 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Rev $1.6B >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Adj EPS $2.83 >STE

11.05.2026 г., 20:22 ч. UTC

Горещи акции

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11.05.2026 г., 19:37 ч. UTC

Печалби

More Bad News at KKR's Private Credit Fund -- Barrons.com

11.05.2026 г., 19:32 ч. UTC

Пазарно говорене

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

45.24% нагоре

12-месечна прогноза

Среден 136.77 USD 45.24%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

320 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.